|
1
|
Swerdlow SH, Campo E, Harris NL, et al:
Atypical chronic myeloid leukaemia, BCR-ABL1 negative. WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues
(4th). Swerdlow SH and Harris NL: (Lyon, France). IARC Press.
80–81. 2008.
|
|
2
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick H, Sultan C and Cox C: The chronic
myeloid leukaemias: guidelines for distinguishing chronic
granulocytic, atypical chronic myeloid and chronic myelomonocytic
leukaemia. Proposals by the French-American-British Cooperative
Leukaemia Group. Br J Haematol. 87:746–754. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galton DA: Haematological differences
between chronic granulocytic leukaemia, atypical chronic myeloid
leukaemia, and chronic myelomonocytic leukaemia. Leuk Lymphoma.
7:343–350. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Breccia M, Biondo F, Latagliata R,
Carmosino I, Mandelli F and Alimena G: Identification of risk
factors in atypical chronic myeloid leukemia. Haematologica.
91:1566–1568. 2006.PubMed/NCBI
|
|
5
|
Cannella L, Breccia M, Latagliata R,
Frustaci A and Alimena G: Clinical and prognostic features of
patients with myelodysplastic/myeloproliferative syndrome
categorized as unclassified (MDS/MPD-U) by WHO classification. Leuk
Res. 32:514–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Broseus J, Alpermann T, Wulfert M, et al:
MPN and MPNr-EuroNet (COST Action BM0902): Age, JAK2(V617F) and
SF3B1 mutations are the main predicting factors for survival in
refractory anaemia with ring sideroblasts and marked
thrombocytosis. Leukemia. 27:1826–1831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang SA, Hasserjian RP, Fox PS, Rogers HJ,
Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J,
Kanagal-Shamanna R, et al: Atypical chronic myeloid leukemia is
clinically distinct from unclassifiable
myelodysplastic/myeloproliferative neoplasms. Blood. 123:2645–2651.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sutherland DR, Nayyar R, Acton E, Giftakis
A, Dean S and Mosiman VL: Comparison of two single-platform
ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and
FACSCanto flow cytometers. Cytotherapy. 11:595–605. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Piazza R, Valletta S, Winkelmann N, et al:
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Nature Genetics. 45:18–24. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oscier DG: Atypical chronic myeloid
leukaemia, a distinct clinical entity related to the
myelodysplastic syndrome? Br J Haematol. 92:582–586. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jaffe ES, Harrris NL, Stein H, et al:
Pathology and Genetics of Tumours of Haematopoietic and Lymphoid
Tissues. World Health Organization Classfication of Tumours (Lyon,
France). IARC Press. 2001.
|
|
12
|
Hernández JM, del Cañizo MC, Cuneo A, et
al: Clinical, hematological and cytogenetic characteristics of
atypical chronic myeloid leukemia. Ann Oncol. 11:441–444. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malcovati L and Cazzola M:
Myelodysplastic/myeloproliferative disorders. Haematologica.
93:4–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pabst T, Mueller BU, Zhang P, et al:
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer
binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat
Genet. 27:263–270. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Montefusco E, Alimena G, Lo Coco F, et al:
Ph-negative and bcr-negative atypical chronic myelogenous leukemia:
biological features and clinical outcome. Ann Hematol. 65:17–21.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koldehoff M, Beelen DW, Trenschel R, et
al: Outcome of hematopoietic stem cell transplantation in patients
with atypical chronic myeloid leukemia. Bone Marrow Transplant.
34:1047–1050. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Issa JP and Kantarjian HM: Introduction:
emerging role of epigenetic therapy: focus on decitabine. Semin
Hematol. 42(3 Suppl 2): S1–S2. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kantarjian H, O'Brien S, Giles F, et al:
Decitabine low-dose schedule (100 mg/m2/course) in
myelodysplastic syndrome (MDS). Comparison of three different dose
schedules. Blood. 106:7082005.
|
|
19
|
Cashen A, Shah A, Helget A, Todt L, Fisher
N and DiPersio J: A phase I pharmacokinetic trial of decitabine
administered as a 3-hour infusion to patients with acute
myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
Blood. 106:527–528. 2005.
|
|
20
|
Liu YL, Emanuel PD and Castleberry RP:
Decitabine, a potential targeted therapeutic for juvenile
myelomonocytic leukemia. Blood. 106:7062005.PubMed/NCBI
|
